Li Zhanzhan, Yang Baishuang, Long Meihua, Chen Jiarong, Zhi Yaofeng, Li Ronggang, Cao Lixue, Yang Shasha, Sun Jingyi, Meng Zijie, Wu Wanting, Mai Yanyang, Zhang Xin, Huang Yanming, Chen Qiong, Liu Aibin
Department of Oncology, Xiangya Hospital, Central South University, Changsha, PR China.
Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, PR China.
J Pathol. 2025 Mar;265(3):302-315. doi: 10.1002/path.6385. Epub 2025 Jan 13.
Aberrant expression of grainyhead-like transcription factor 3 (GRHL3) has been extensively reported in the development and progression of several squamous cell carcinomas, such as cutaneous, head and neck, and esophageal squamous cell carcinoma. However, the clinical significance and biological roles of GRHL3 in lung squamous cell (LUSC) carcinoma are largely unclear. Herein, we report that GRHL3 was significantly upregulated in lung squamous epithelium of LUSC tissues, bronchiole, and bronchus. Moreover, expression levels of GRHL3 were decreased with the advance of pathological grade, and low GRHL3 level presented poor overall survival and short progression-free and distant metastasis-free survival in LUSC patients but had no prognostic significance in LUAD patients. Functional experiments in vivo showed that downregulating GRHL3 promoted not only lung colonization and growth but also multiple organ distant metastasis of LUSC cells, including bone, brain, and liver. Moreover, silencing GRHL3 promoted anoikis resistance and cancer stem cell (CSCs) characteristics of LUSC cells in vitro. Mechanistically, silencing GRHL3 stabilized SOX2 via SIRT1-mediated decreasing acetylation and subsequent ubiquitination-dependent degradation in LUSC cells. Thus, in-depth understanding of the underlying mechanism of GRHL3 in the progression of LUSC will facilitate the development of prognostic biomarker and therapeutic avenues against LUSC, which will present favorable prospects in improving outcomes of LUSC patients. © 2025 The Pathological Society of Great Britain and Ireland.
颗粒头样转录因子3(GRHL3)的异常表达在多种鳞状细胞癌(如皮肤、头颈部和食管鳞状细胞癌)的发生发展中已有广泛报道。然而,GRHL3在肺鳞状细胞癌(LUSC)中的临床意义和生物学作用尚不清楚。在此,我们报告GRHL3在LUSC组织的肺鳞状上皮、细支气管和支气管中显著上调。此外,GRHL3的表达水平随着病理分级的进展而降低,低GRHL3水平提示LUSC患者的总生存期较差,无进展生存期和无远处转移生存期较短,但对肺腺癌(LUAD)患者无预后意义。体内功能实验表明,下调GRHL3不仅促进LUSC细胞的肺定植和生长,还促进其向包括骨、脑和肝在内的多个器官的远处转移。此外,沉默GRHL3可促进LUSC细胞在体外的失巢凋亡抗性和癌症干细胞(CSC)特性。机制上,沉默GRHL3通过SIRT1介导的乙酰化降低和随后LUSC细胞中泛素化依赖性降解来稳定SOX2。因此,深入了解GRHL3在LUSC进展中的潜在机制将有助于开发针对LUSC的预后生物标志物和治疗途径,这将为改善LUSC患者的预后带来良好前景。© 2025英国和爱尔兰病理学会